Submitted by Anonymous (not verified) on 10 August 2026 - 9:33
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 23, Status: Authorised
Source: